EyePoint Pharmaceuticals Strengthens Leadership Team with Addition of Scott Jones and Said Saim


WATERTOWN, Mass.—EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, has appointed Scott Jones as chief commercial officer and Said Saim, PhD, as chief technology officer, according to an announcement on Monday. Jones brings to EyePoint significant experience commercializing drugs and devices. Most recently, he served as chief commercial officer and vice president, business development at Notal Vision, where he developed commercial and growth strategies. His tenure at Notal Vision included a stint as president, a time when he was responsible for developing a business model that would allow for a telemonitoring platform to be covered by Medicare.

Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following cataract surgery, and Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Saim will be responsible for advancing EyePoint’s pipeline products and technology for ocular treatments from formulation, preclinical research up to clinical development, as well as pharmaceutical sciences, manufacturing and operations. Previously, Saim was vice president, pharmaceutical development at Collegium Pharmaceutical.

“Scott and Said both bring a wealth of experience and expertise in the specialty pharmaceutical industry, and we are pleased to welcome them to our growing team as we establish EyePoint’s status as a leading commercial-stage ophthalmology company,” president and chief executive officer Nancy Lurker said in the announcement. “The launches of our two ophthalmology products have been met with strong interest from both patients and treating physicians for these debilitating eye diseases. We look forward to leveraging Scott and Said’s respective expertise to drive growth of our market share for our newly-launched products and to continue the advancement of our pipeline to bring additional innovative products to market for treatments with high medical need.”